NextCure, Inc. Share Price
NXTCNextCure, Inc. Stock Performance
Open $2.60 | Prev. Close $2.77 | Circuit Range N/A |
Day Range $2.38 - $2.60 | Year Range $0.40 - $15.61 | Volume 4,590 |
Average Traded $2.54 |
NextCure, Inc. Share Price Chart
About NextCure, Inc.
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fusion protein of LAIR-2, that is designed to block immune suppression mediated by LAIR-1; NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leukemic stem cells; NC181 a humanized antibody targeting ApoE4 for the treatment of Alzheimer's disease; and NC605 an antibody that targets Siglec-15, as well as chronic bone diseases, such as osteoarthritis and non-union fractures. The company also develop SIM0505, a novel antibody-drug conjugate (ADC) targeting CDH6 (cadherin-6 or K-cadherin) for the treatment of solid tumors. NextCure, Inc. was incorporated in 2015 and is headquartered in Beltsville, Maryland.
NextCure, Inc. Historical Data
| Day | Open | Close | Change % |
|---|---|---|---|
09-Jun-26 | $2.60 | $2.31 | +0.00% |
09-Jun-26 | $2.60 | $2.31 | -16.46% |
08-Jun-26 | $2.91 | $2.77 | -4.98% |
05-Jun-26 | $2.96 | $2.91 | -8.49% |
04-Jun-26 | $3.27 | $3.18 | +0.32% |
03-Jun-26 | $3.32 | $3.17 | -5.65% |
02-Jun-26 | $3.55 | $3.36 | +1.82% |